Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice.
Pancreatic cancer in a common tumor in our country for which there are various treatment alternatives. Evaluate the effectiveness and safety of nab-paclitaxel and gemcitabine in everyday clinical practice. Observational, retrospective study at a tertiary university hospital. We included patients diagnosed of metastatic or locally advanced pancreatic cancer that were being treated with nab-paclitaxel and gemcitabine. We recorded response, progression-free survival (PFS), and overall survival (OS) rates together with toxicities. We used SPSS program for Windows. We conducted descriptive statistics using averages, medians, standard deviations or ranges, and percentages. We included 15 patients. At 3 months, there were no complete responses; 20% showed partial responses, and in 60% of patients, the disease stabilized. The median PFS was 8.9 months and the OS was 9.6. The most important adverse reactions were neutropenia, fatigue, and nausea/vomiting. The treatment regimen leads to increased survival in these patients with an acceptable toxicity profile.